ICI

ICI. Immune checkpoint inhibitors are a class of pharmaceutical drug that revolutionised the treatment of various cancers by harnessing the body's own immune system. These therapeutic agents work by blocking inhibitory pathways, known as immune checkpoints, on T cells or tumor cells, thereby enhancing the antitumor immune response. Their development, stemming from foundational research in immunology, has provided durable responses for patients with historically poor prognoses, such as those with metastatic melanoma and non-small cell lung cancer.

Definition and Overview

Immune checkpoint inhibitors are a form of immunotherapy specifically designed to interfere with regulatory pathways that suppress T cell activation. The most prominent targets are the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein 1 (PD-1) pathway, which includes PD-1 and its ligand PD-L1. By administering monoclonal antibodies against these proteins, the "brakes" on the immune system are released, allowing lymphocytes to more effectively recognize and destroy malignant cells. This approach represents a paradigm shift from traditional cytotoxic chemotherapy and has been integrated into treatment guidelines globally, including those from the National Comprehensive Cancer Network.

Applications and Uses

The clinical use of immune checkpoint inhibitors has expanded rapidly since the first approvals by the U.S. Food and Drug Administration. They are now standard-of-care for a wide array of malignancies, including advanced melanoma, renal cell carcinoma, Hodgkin lymphoma, and certain colorectal cancers with microsatellite instability. Landmark trials such as CheckMate 067 and KEYNOTE-001 demonstrated unprecedented survival benefits in patients with metastatic disease. Furthermore, these agents are being investigated in neoadjuvant and adjuvant therapy settings for earlier-stage cancers and are being combined with other modalities like radiation therapy and targeted therapy.

Mechanism of Action

The mechanism centers on disrupting the interaction between T cell receptors and co-inhibitory molecules expressed on antigen-presenting cells or tumor cells. For instance, ipilimumab binds to CTLA-4, a protein that downregulates the early stages of T cell activation primarily in lymph nodes. Conversely, nivolumab and pembrolizumab target the PD-1 receptor, blocking its engagement with PD-L1 often upregulated in the tumor microenvironment. This blockade prevents the transmission of inhibitory signals, leading to enhanced T cell proliferation, increased cytokine production, and ultimately, apoptosis of cancer cells. The immune response can also lead to unique inflammatory side effects known as immune-related adverse events.

History and Development

The scientific foundation was laid by researchers like James P. Allison of the University of Texas MD Anderson Cancer Center and Tasuku Honjo of Kyoto University, whose work on CTLA-4 and PD-1, respectively, earned them the Nobel Prize in Physiology or Medicine in 2018. The first clinical breakthrough came with the development of ipilimumab, which showed a survival benefit in metastatic melanoma in a pivotal study published in the New England Journal of Medicine. This success spurred the development of subsequent agents targeting the PD-1/PD-L1 axis, such as nivolumab from Bristol Myers Squibb and pembrolizumab from Merck & Co., transforming the oncology landscape.

Related Terms and Concepts

The field of cancer immunotherapy encompasses several related approaches, including adoptive cell transfer like CAR-T cell therapy and cancer vaccines. The therapeutic effect of immune checkpoint inhibitors is closely tied to the concept of tumor mutational burden and the presence of tumor-infiltrating lymphocytes. Managing treatment involves monitoring for immune-related adverse events such as colitis, pneumonitis, and endocrine disorders. Other investigational checkpoint targets include LAG-3, TIM-3, and TIGIT, with agents like relatlimab showing promise in combination regimens. Category:Immunotherapy Category:Oncology Category:Monoclonal antibodies